Sagaliam Acquisition (SAGAR) 10-Q2023 Q1 Quarterly report

Filed: 27 Nov 23, 5:25pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. senior Bad

New words: AEC, backed, BCA, belief, BGEN, binding, Clerk, cont, directed, ENZC, GLD, Insider, Jan, lawsuit, Legacy, LMI, LP, Metaverse, Nov, nutraceutical, NYF, October, OTC, owed, Pending, PIPE, PK, precondition, profit, restructured, SAGA, scheduled, Seacor, Sep, Sept, strike, Superior, supplemental, Supraeon, thousand, Unregistered, viable, vigorously, VIRO, warrant

Removed: compute, denominator, numerator, reconciliation, table

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

SAGAR similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Sagaliam Acquisition Corp. (the “Company”) on Form 10-Q for the quarterly period ending March 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, in the capacity and on the date indicated below, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 27, 2023

	/s/ Barry Kostiner
	Barry Kostiner
	Chief Executive Officer
	(Principal Executive Officer and Principal Financial Officer)

[Signature Page to Officer Certificate]

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.